Sandoz, a global leader in generic and biosimilar medicines, today announced the launch in the United States of its generic combination eye drop brimonidine tartrate/timolol maleate ophthalmic solution 0.2 percent/0.5 percent, an AB-rated generic equivalent to AbbVie’s COMBIGAN, to treat ocular hypertension in patients (high eye pressure). Patients can get this prescription eye drop right away at a retail pharmacy.
Ocular hypertension can affect anybody, although it is more common in African Americans and Hispanics, persons over the age of 40, people with diabetes or high blood pressure, people who are severely myopic (near-sighted), and people who take long-term steroid medications. It’s critical to treat high eye pressure before it damages the optic nerve and results in visual loss.
“Fixed combinations of medicines to treat ocular hypertension can offer patients enhanced convenience, improved adherence, reduced exposure to preservatives, and cost savings. We developed this important generic eye treatment in-house to expand patient access to high-quality, more affordable eye care for millions of US patients,”said Keren Haruvi, President, Sandoz Inc.
With over 36 product families for the treatment of a wide range of eye conditions, Sandoz is a leading provider of ophthalmic pharmaceuticals in the United States. Sandoz’s ophthalmology portfolio has been expanded with the launch of generic brimonidine tartrate/timolol maleate combination eye drops in the United States, helping the company maintain its #1 position in the US generic ophthalmic arena.
Contact us with your feedback and suggestions.